Thermo Fisher Scientific (NYSE:TMO) Share Price Crosses Below 50 Day Moving Average – Here’s Why

Thermo Fisher Scientific Inc. (NYSE:TMO – Get Free Report) crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $678.63 and traded as low as $667.94. Thermo Fisher Scientific shares last traded at $668.8920, with a volume of 2,360,257 shares.

Top Thermo Fisher Scientific Stories

Here are a few of the latest stories about TMO:

Analysts Set New Price Targets

A number of equities analysts recently issued reports on TMO shares. HSBC upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating and upped their price objective for the stock from $660.00 to $690.00 in a research report on Tuesday, September 1st. Deutsche Bank upped their price target on shares of Thermo Fisher Scientific from $720.00 to $750.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. CLSA initiated coverage on Thermo Fisher Scientific in a report on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 price objective on the stock. Rothschild & Co Redburn upped their target price on Thermo Fisher Scientific from $725.00 to $750.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. Finally, Evercore lowered their price objective on Thermo Fisher Scientific from $720.00 to $615.00 and set an “outperform” rating for the company in a research note on Wednesday, October 28th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $683.64.

View Our Latest Stock Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Performance

The company has a debt-to-equity ratio of 0.71, a current ratio of 1.81 and a quick ratio of 1.41. The stock has a fifty day simple moving average of $678.63 and a two-hundred day simple moving average of $559.30. The firm has a market capitalization of $247.84 billion, a P/E ratio of 35.28, a P/E/G ratio of 2.73 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, beating the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The company had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same period last year, the business posted $5.79 EPS. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Tuesday, December 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.92%.

Insider Buying and Selling

In other news, CEO Marc Casper sold 275 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $77,707,171.25. This represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 2,831 shares of the firm’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $706.45, for a total value of $1,999,959.95. Following the completion of the transaction, the vice president owned 11,560 shares in the company, valued at $8,166,562. This represents a 19.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several large investors have recently added to or reduced their stakes in TMO. WNY Asset Management LLC purchased a new stake in Thermo Fisher Scientific during the 3rd quarter worth about $210,000. Stonebrook Private Inc. bought a new stake in shares of Thermo Fisher Scientific during the third quarter valued at about $253,000. American Century Companies Inc. increased its position in shares of Thermo Fisher Scientific by 294.1% during the third quarter. American Century Companies Inc. now owns 358,220 shares of the medical research company’s stock valued at $241,816,000 after buying an additional 267,323 shares during the period. Innovative Asset Advisors Group LLC lifted its holdings in shares of Thermo Fisher Scientific by 6.0% in the third quarter. Innovative Asset Advisors Group LLC now owns 424 shares of the medical research company’s stock worth $286,000 after buying an additional 24 shares in the last quarter. Finally, PCM Encore LLC boosted its position in shares of Thermo Fisher Scientific by 3.1% in the third quarter. PCM Encore LLC now owns 1,442 shares of the medical research company’s stock valued at $974,000 after acquiring an additional 44 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.

Recommended Stories

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.